MAbSilico: AI That Turns Antibody Discovery Into a 21-Day Advantage
Overview: How MAbSilico’s AI-Driven Antibody Discovery & Engineering Platform Transforms Biologics R&D MAbSilico is an AI-driven antibody discovery and engineering platform that helps teams design and optimise antibody candidates within the early biologics R&D pipeline. In a field where traditional discovery can be slow, resource-intensive, and constrained by the need to balance affinity, specificity, developability, […]
Feature Categories
Overview: How MAbSilico’s AI-Driven Antibody Discovery & Engineering Platform Transforms Biologics R&D
MAbSilico is an AI-driven antibody discovery and engineering platform that helps teams design and optimise antibody candidates within the early biologics R&D pipeline. In a field where traditional discovery can be slow, resource-intensive, and constrained by the need to balance affinity, specificity, developability, and manufacturability, the platform is positioned to reduce the time and uncertainty involved in identifying promising lead molecules.
At a high level, MAbSilico applies computational modelling and machine learning to analyse antibody-target interactions, support de novo design, and guide lead optimisation before teams commit to costly experimental cycles. By helping researchers prioritise better candidates earlier, it can streamline decision-making and reduce reliance on broad, trial-and-error screening. For research and development teams, this can translate into faster progression from target to lead, fewer wasted lab iterations, and a more focused path toward selecting antibodies with stronger therapeutic potential.
Last checked on July 28, 2026: MAbSilico remains active, with live positioning centred on AI-enabled antibody design and a recent AI-guided epitope mapping partnership.
What is MAbSilico?
MAbSilico is an AI-enabled antibody discovery and engineering platform that supports therapeutic antibody design, epitope mapping, affinity prediction, and lead optimisation. It appears to be aimed at biotech and pharma R&D teams rather than clinicians or hospitals, and it differentiates itself through an in silico workflow that combines 3D modelling, interaction simulation, sequence analysis, and biological validation.
Public sources describe its outputs as evaluated for epitope, off-target risk, cross-reactivity, and developability, with recent activity including an AI-guided epitope-mapping partnership.
Why Do Leading Healthcare Teams Trust MAbSilico?
-
MAbSilico has active commercial and partnership activity, including an exclusive 2025 collaboration with YntoAb to offer AI-based antibody analysis services in South Korea.
-
The company has an ongoing multi-year collaboration history with OSE Immunotherapeutics, a biotechnology partner using MAbSilico’s AI technology for antibody programmes.
-
MAbSilico received a Bpifrance i-Nov grant of 1 million euros for its antibody-discovery software, which is a material external validation signal.
-
A 2025 partner update says MAbSilico’s research was published in Frontiers in Immunology, which supports scientific credibility through peer-reviewed validation.
-
Public descriptions state that its platform is used for therapeutic and biomarker antibody discovery and development, with outputs including epitope, affinity, off-target risk, cross-species reactivity, and developability assessment.
-
The company’s technology is described as combining AI, 3D modelling, interaction simulation, and sequence analysis rather than relying on a purely generative or black-box approach.
-
Recent statements indicate MAbSilico achieved break-even in 2025, which may support operational stability, although this comes from company self-reporting.
Follow HealthyData.Science on Google Search & AI
Get our latest healthcare and life science AI tool evaluations, regulatory updates, and buyer intelligence in your Google AI Overviews.
Add as Preferred SourceGet a neutral, no obligation view of whether this AI tool fits your portfolio
